SAN DIEGO, CA--(Marketwire - April 5, 2011) - Therapeutic Solutions International, Inc. (
"The NTI Tension Suppression System is the most effective non-drug FDA-approved method of migraine prevention on the market today," stated James P. Boyd, DDS, Director of Research and Product Development of Therapeutic Solutions International, Inc. (TSI). "This rounds out TSI's product line of cost effective, therapeutic and provisional intraoral one-visit devices."
In addition to the newly added NTI to their product line, TSI also boasts its "Total Splint Solution," for those patients whose practitioner has diagnosed them with bruxism, snoring, apnea, or migraine.
"We are thrilled to conclude this significant license agreement," stated Tim Dixon, President of TSI. "The NTI Tension Suppression System is a group of products based on patented technology. The Agreement gives TSI the exclusive worldwide rights governing the inventions, technology, know-how, patents and patent applications for the NTI."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. is a company whose business plan is focused on the development, production and marketing of cost effective technologies and therapeutic modalities for the treatment and prevention of common neurologic, sleep and temporomandibular disorders. TSI has several important websites to disseminate information and market their products. Our clinical research site for the NTI is www.nti-tss.com and our e-commerce portal is located at www.ordertsi.com. Our patient education site located at www.headacheprevention.com, and our corporate website for TSI is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.